Clinical-stage biotechs run on two clocks: the trial timetable and the cash runway. Paradigm Biopharmaceuticals (ASX:PAR) was working the second of those on 11 September 2026, drawing the fourth Tranche under its convertible note Facility and lodging the related Quotation and disclosure notices the same day. The Melbourne company is developing an injectable formulation of pentosan polysulfate sodium as a non-opioid treatment for knee osteoarthritis, a large indication with a well-documented shortage of Options between simple painkillers and joint replacement surgery.

Latest Development

Paradigm lodged four announcements on 11 September 2026. The substantive one was the drawdown of tranche 4 under its convertible note facility, accompanied by an application for quotation of securities, a notice under section 708A of the Corporations Act and a notification regarding unquoted securities.

Section 708A notices are the mechanism by which shares issued without a disclosure document become freely tradeable, so the package indicates the drawdown converted into issued equity. For a company without product revenue, the pace of drawdowns under a convertible facility is a direct read on how development spending is financed.

The company had hosted a Melbourne investor lunch on 2 September 2026.

Company Overview

Paradigm Biopharmaceuticals Limited is a Melbourne-headquartered biopharmaceutical company that listed on the ASX on 19 August 2015. It develops therapeutic products for human use, with a stated emphasis on non-opioid approaches to pain and disease modification.

Its lead asset is an injectable formulation of pentosan polysulfate sodium, known as iPPS and branded Zilosul, targeted at knee osteoarthritis. The company has advanced the compound into a phase 3 programme, with the PARA_OA_002 trial the central study. Knee osteoarthritis is among the most common causes of chronic disability in ageing populations, and the treatment gap between analgesics and surgery is what the company is positioning against.

Earlier work reported by Paradigm includes phase 2 data indicating that iPPS reduced cartilage loss and improved function in osteoarthritis patients, and a phase 2b study that met key secondary endpoints for improved knee function with benefit reported out to six months. The company has also previously operated an expanded access programme in the United States.

Financial and Operational Position

Paradigm is pre-revenue and has never paid a dividend, reporting a loss per share of 15.2 cents. Market Capitalisation was approximately A$173 million as at 11 September 2026.

Financing is running through the convertible note facility, with tranche 4 drawn on 11 September 2026. Institutional custodians sit at the top of the register, with Citicorp Nominees on 5.19% and HSBC Custody Nominees on 3.61%.

What Investors May Watch Next

Read-outs and regulatory interactions from the phase 3 programme are the events with the greatest bearing on value, and any announcement concerning PARA_OA_002 would be closely followed.

On the funding side, the size and timing of any further convertible note tranches, the conversion terms attaching to them and the resulting share count are identifiable markers. Quarterly Cash Flow reports and any partnering or licensing discussions round out the near-term calendar.

Risks

Clinical development carries binary risk. A phase 3 trial can miss its endpoints regardless of encouraging earlier data, and regulatory approval is never assured.

Convertible note funding can be dilutive, particularly where conversion is priced off a discounted market reference, and the share count can expand materially. The company has no product Revenue and remains dependent on external capital. Reimbursement, pricing and clinician adoption would all have to fall into place before revenue arrives.

Conclusion

Paradigm could remain in focus this September because of what happened on 11 September 2026: a fourth convertible note drawdown and the associated share issue notices, disclosed on the same day. That keeps the Balance Sheet funded while the phase 3 programme for injectable pentosan polysulfate sodium runs. For a company targeting knee osteoarthritis without opioids, the outlook may depend on clinical data and on how much Equity the funding structure ultimately requires.